65,437 trials
Distal Urethral Cancer · Proximal Urethral Cancer · Recurrent Bladder Cancer
Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants
Venous Thromboembolism
Primary: Time Spent Per PT/INR Monitoring Encounter — 19.4; 47 minutes
Pregnancy; Habitual Aborter · Weeks of Gestation 37 or More
Primary: The Mean Positive Percentage Agreement (PPA) for Fetal Heart Between Device 1 Monica AN24 & Device 2 Philips 50XM — 84.85 Positive percantage agreement (PPA)
Lipid Metabolism, Inborn Errors · Hypercholesterolemia, Autosomal Dominant · Hyperlipidemias
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point — -3.31; -24.66 percentage of baseline — p=<0.001
ALPS · Hypersplenism · Lymphadenopathy
Primary: Number of Participants With Response — 0 participants
Prostate Cancer
Primary: Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight — 3; 6; 3; 6 participants
Hypercholesterolemia · Coronary Heart Disease
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point — 12.5; -35.9 percentage of baseline — p=<0.001
Post Herpetic Neuralgia
Primary: Change From Baseline to End of Study in LOCF VAS — -20.4; -21.3 scores on a scale
Primary Immune Deficiency
Primary: IgG Trough Level — 1.09; 1.11 Ratio of Geometric Means
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Number of Confirmed Responses (Complete Response, Partial Response, or Hematologic Improvement) Noted on 2 Consecutive Evaluations at Least 4 Weeks Apart — 1; 0; 0…
COPD
Primary: Exercise Tolerance Comparison Between QVA149 and Placebo Groups — 507.8; 448.3 Seconds
Hypercholesterolemia · Coronary Heart Disease
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point — -3.4; -40.2 percentage of baseline — p=<0.001
Migraine Disorders
Primary: Subject Self-examination of Skin Irritation — 0.6 scores on a scale
Neoplasm
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Heart Failure, Congestive · Ventricular Dysfunction · Cardiomyopathies
Primary: Survival — 112; 6; 18; 19 participants